Reports Q3 revenue $1.37B, consensus $1.25B. “Our third-quarter results demonstrate strong growth across our product portfolio, with net product revenues increasing 19% year-over-year, which highlights the momentum in our business and effective commercial execution,” said Bill Meury, president and CEO, Incyte (INCY). “We are taking a deliberate approach to pipeline prioritization. We are actively reviewing our R&D efforts and focusing on high-value programs that are scientifically differentiated, address unmet medical needs, and have the potential to significantly drive Incyte’s next phase of growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s Ruxolitinib Cream Study: A Potential Game-Changer for Hidradenitis Suppurativa
- Incyte’s Ruxolitinib Cream Study: A Potential Breakthrough for Pediatric Vitiligo
- Incyte’s Latest Clinical Study: A Step Forward in Drug Development
- Incyte’s Phase 3 Study on Povorcitinib: A Potential Game-Changer for Prurigo Nodularis
- Incyte’s Promising Phase 3 Study on Axatilimab for cGVHD: What Investors Should Know